相关实验视频
Updated: Jun 26, 2025

09:10
Synthesis of Indoxyl-glycosides for Detection of Glycosidase Activities
Published on: May 27, 2015
6.6K
作为潜在的glyoxalase-I抑制剂的新型 antraquinone 胺基衍生物
Mohammed Al-Akeedi1, Manal Najdawi1, Qosay Al-Balas2
1Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan.
Journal of medicine and life
|May 13, 2024
概括
研究人员发现了新的 antraquinone 胺基衍生物,可以抑制 Glyoxalase-I (Glo-I),一种与癌症有关的酶. 化合物MQ3通过有效地阻断Glo-I活性,显示出作为抗癌剂的显著潜力.
科学领域:
- 药用化学 医学化学
- 酶学 是一种酶学.
- 癌症生物学 癌症生物学
背景情况:
- 氧酶-I (Glo-I) 是细胞解毒途径中的一个关键酶.
- 升高的Glo-I活性与各种癌症有关,使其成为一个有前途的治疗点.
- 需要新的抑制剂来有效地针对Glo-I用于癌症治疗.
研究的目的:
- 为了合成和评估新的以胺为基础的 antraquinone 衍生物作为 Glyoxalase-I (Glo-I) 抑制剂.
- 为了研究这些衍生品的结构-活性关系 (SAR) 对Glo-I抑制.
- 评估最有效的Glo-I抑制剂的抗癌潜力.
主要方法:
- 一系列 antraquinone 胺基衍生物的合成.
- 在基分子对接研究中,预测与Glo-I.I.的结合相互作用.
- 在体外酶抑制试验测定抗Glo-I活性 (IC50值).
- 分子动力学模拟以评估结合稳定性.
主要成果:
- 化合物MQ3表现出强大的Glo-I抑制活性,IC50为1.45μM.
- SAR分析确定了关键的结构特征 (甲基醇环,胺, antraquinone),有助于强大的抑制.
- 分子动力学证实了MQ3与Glo-I的稳定结合.
结论:
- 氨基胺衍生物代表了一个有前途的新型Glo-I抑制剂.
- 化合物MQ3显示出作为向Glo-I的抗癌剂的显著潜力.
- 对这些衍生物的进一步研究可能会导致新的癌症疗法.
相关概念视频
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
Oral Hypoglycemic Agents: Glinides
153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
2.9K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
2.9K

![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)